Psyence Group Inc.
WKN: A2QNE2 | ISIN: CA74449Q1063 | CSE: PSYG | OTCQB: PSYGF 

Psyence is a life science biotechnology company. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psyence is focused on developing proprietary natural psilocybin drug development and treatment protocols. Psyence is developing market leading clinical trials in the field of palliative care.

Clinical trial programme

Psyence’s clinical trials will assess the safety and efficacy of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis in a palliative care context.

In the United Kingdom, Psyence has partnered with Clerkenwell Health, a leading psychedelic contract research organisation (CRO). Clerkenwell will be responsible for jointly designing and delivering Psyence’s UK clinical trials in the future. Psyence has received Phase IIa clinical trial approval from the UK Medicines and Healthcare Products Regulatory Agency (in September 2022) to commence its UK clinical trial.

Psyence has also signed a Letter of Intent (LOI) with iNGENū CRO, a globally focused CRO with extensive experience in working in the psychedelic pharmaceutical drug development and clinical research industry. iNGENū will be responsible for jointly designing Psyence’s Phase IIb clinical trial to be conducted in Australia. The LOI centres around Psyence’s global development and regulatory strategy of its licensed compound PEX010 in palliative care in Phase II clinical trials. The prospective cooperation and trial would potentially reduce Psyence’s timeline for starting a Phase III registrational clinical trial.

On 9 January 2023, Psyence Biomed, a wholly owned subsidiary of Psyence Group, announced that it has entered into a definitive business combination agreement with Newcourt Acquisition Corp (Nasdaq: NCAC) to create a public company leveraging psilocybin in the treatment of palliative care. Psyence biomed is Psyence’s clinical trial division. The combined company would be capitalized with a minimum of US$ 20 million, have access to Nasdaq listed Newcourt shareholders, promoters, and advisors. The business combination is anticipated to conclude in the first half of 2023 with the combined company to go public. The funding from the transaction will enable Psyence to execute its early-stage development programme in palliative care.

Licensed producer of psilocybin

Psyence operates one of the first and only federally licensed commercial psilocybin production facilities in the world. Its facility, located in Southern Africa, is ISO22000 certified and is licensed to cultivate and export psilocybin mushrooms for the legal, global medical market and commercial medical research market.

Advanced Blockchain AG
WKN: A0M93V | ISIN: DE000A0M93V6 | DSE: ABX

Advanced blockchain AG is a blockchain venture builder focused on investing, developing, and scaling in disruptive technologies including token investments. Their main market is there-fore the venture capital market for companies active in blockchain technology, with a particular focus on the decentralized finance (DeFi) sector and infrastructure projects enabling Web 3.0. Advanced Blockchain AG is an innovation center with a diversified portfolio consisting of internal projects, incubations as well as early-stage investments. The venture builder arm of Advanced Blockchain AG acts as a leading incubator of projects such as for Composable Finance and Quasar. Extensive expertise, resources and networks provide the company with early-stage access to exclusive investment opportunities in projects with significant potential.

Advanced blockchain AG is listed in the Scale segment of Deutsche Börse, as well as in the primary market of Börse Düsseldorf.

GoviEx Uranium Inc.
WKN: A12BL3 | ISIN: CA3837981057 | TSX: GXU | FSE: 7GU

GoviEx is a diversified mineral resource company focused on the exploration and development of uranium properties in Africa. GoviEx’s principal objective is to become a significant uranium producer in this uranium cycle through the continued exploration and development of its mine permitted projects, namely the Madaouela Project in Niger and the Muntanga Project in Zambia. 

coinIX GmbH & Co. KGaA
WKN: A2LQ1G | ISIN: DE000A2LQ1G5 | DSE: XCX

coinIX GmbH & Co. KGaA was founded in 2017 to build expertise in the field of cryptocurrencies and blockchain-based business models. This allows to participate in the growth potential of this emerging market and at the same time to benefit from a long-term positive performance of the acquired assets. 

The portfolio of coinIX is composed of liquid cryptocurrencies, classic investments in start-ups and token projects in which digital assets are acquired that are not yet listed on a marketplace. 

Knaus Tabbert AG
WKN: A2YN50 | ISIN: DE000A2YN504 | FSE: KTA

Knaus Tabbert AG is a leading manufacturer of Caravans and Mobile Homes in Europe with headquarters in Jandelsbrunn, Bavaria. Further locations in Germany are Mottgers and Schlüsselfeld as well as Nagyoroszi in Hungary. The company has been listed in the Prime Standard segment of the Frankfurt Stock Exchange (ISIN: DE000A2YN504) since September 2020 and in 2021 generated sales of just under 850 million euros with its KNAUS, TABBERT, T@B, WEINSBERG, MORELO and RENT AND TRAVEL rental service brands and produced more than 25,000 recreational vehicles with around 3,500 employees.

UniDevice AG
WKN: A11QLU | ISIN: DE000A11QLU3 | FSE: UDC

UniDevice AG (with PPA International AG) is an international B2B broker for communication and consumer electronics with a focus on high-priced smartphones from leading manufacturers such as Apple and Samsung. In this market, the Berlin-based company is the first in Germany to specialize in optimizing customers‘ supply chains. Customers include mobile service providers as well as wholesalers and retailers. Risks are much lower than with a wholesaler because of the fast inventory turnover and immediate payment of customers.

POWER METALLIC MINES INC.
WKN: A40S32 | ISIN: CA73929R1055 | FSE: IVV0  | TSX-V: PNPN

Power Nickel is a Canadian junior exploration company focusing on developing the High-Grade Nickel Copper PGM, Gold and Silver Nisk project into Canada’s next poly metallic mine.

On February 1, 2021, Power Nickel (then called Chilean Metals) completed the acquisition of its option to acquire up to 80% of the Nisk project from Critical Elements Lithium Corp. (CRE: TSXV).

The NISK property comprises a large land position (20 kilometres of strike length) with numerous high-grade intercepts. Power Nickel is focused on expanding the high-grade nickel-copper PGM, Gold and Silver mineralization with a series of drill programs designed to test the initial Nisk discovery zone, the Lion discovery zone and to explore the land package for adjacent potential poly metallic deposits.

In addition to the Nisk project, Power Nickel owns significant land packages in British Colombia and Chile. Power Nickel is expected to finalize the reorganization ofthese assets in a related vehicle through a plan of arrangement.

META MATERIALS INC
WKN: A3CSM6 | ISIN: US59134N1046 | FSE: MMAT | NASDAQ: MMAT

META® (Meta Materials Inc.) is a smart materials and photonics company that is changing the way we use, interact, and benefit from light. Through applied physics and advanced design, we are pioneering a new class of multi-functional materials—called metamaterials— which have engineered properties that go beyond what is found in nature.

Almost every great advancement in technology can be attributed to a breakthrough in material science. The Stone, Bronze and Iron Ages were enabled by taking advantage of new tools for writing, warfare and irrigation, driven by the manipulation of the raw materials of stone, bronze and iron.

The Industrial Revolution was enabled by the harnessing of steam power, driven in large part by advancements in the manipulation of steel and metals. In the last 60 years, the Digital Age in which we now live was enabled by the invention of the transistor, driven by the discovery of semiconducting materials and the means to manipulate their properties.

We are now in the beginning of another revolution in materials science, driven by advancements in the “invisible” world of nanotechnologies, Artificial Intelligence (AI) to design new materials, and metamaterials.

At META we design and manufacture functional materials that are more sustainable, higher performing and cost less than the competition. These are complex, structured materials that perform special functions, utilizing light and other forms of energy in new and often surprizing ways. Our products are designed using algorithms and engineered at microscopic levels, creating novel functional materials that mimic nature and metamaterials with new properties and capabilities that go beyond those found in natural materials.

First Phosphate Corp.

WKN: A1J81V | ISIN: CA33611D1033 | CSE: PHOS | FSE: KD0

First Phosphate (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) is a mineral development company fully dedicated to extracting and purifying phosphate for the production of cathode active material for the Lithium Iron Phosphate (“LFP”) battery industry. First Phosphate is committed to producing at high purity level, in a responsible manner and with low anticipated carbon footprint.

First Phosphate plans to vertically integrate from mine source directly into the supply chains of major North American LFP battery producers that require battery grade LFP cathode active material emanating from a consistent and secure supply source.

First Phosphate is owner and developer of the Bégin-Lamarche Property in Saguenay-Lac-St-Jean, Quebec, Canada that consists of rare anorthosite igneous phosphate rock that generally yields high purity phosphate material devoid of harmful concentrations of deleterious elements.

DEFENCE THERAPEUTICS INC.
WKN: A3CN14 | ISIN: CA24463V1013 | FSE: DTC 

Defence Therapeutics are Canadian scientific pioneers on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations. Leading the way with targeted science, strategic products and bold curiosity, we are uncovering micro and macro level methods, bringing catalytic change to future patients.

With the patented Accum technology, Defence Therapeutics offers a platform for so-called antibody-drug conjugates (ADC). In this process, a specific active ingredient is linked to an antibody by means of a peptide linker and thus reaches precisely where it is supposed to act. For example, into a tumor cell. Defence Therapeutics has data showing that Accum can significantly increase the efficacy of certain forms of therapy in combination with immune checkpoint inhibitors. Immune checkpoint inhibitors are targeted in oncology to block anti-inflammatory immune checkpoints to provide benefits during therapy.